Jiangsu Hengrui Pharmaceuticals Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is OXALIPLATIN USP, with a corresponding US DMF Number 20665.
Remarkably, this DMF maintains an Active status since its submission on July 09, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 03, 2013, and payment made on December 24, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II